Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy
Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy
复制标题
DOI：
10.1007/s00262-018-2285-y
复制
发表时间：
2019-01-01
影响因子：
5.8
通讯作者：
Ibrahim, Ramy
中科院分区：
文献类型：
--
作者：
Maio, Michele;Coukos, George;Ibrahim, Ramy
2017年10月，在意大利锡耶纳举行了一次由免疫肿瘤学网络、临床/转化研究者和制药行业的专家组成的合作智库会议，讨论不断发展的免疫肿瘤学前景，确定选定的关键挑战，并就将当前研究和知识转化为临床现实所需的后续步骤提供观点。虽然存在组合新药剂（例如，在使用PD-1/PD-L1治疗主干的情况下，还应考虑使用替代联合治疗方法。虽然系统生物学的快速发展提供了对肿瘤和肿瘤微环境异质性的更深入理解，但仍然需要识别和定义真正的预测性生物标志物，以指导治疗和患者选择。跨专业和跨部门合作，沿着更广泛的集体数据共享方法，是优化临床实践中免疫肿瘤治疗的关键。继续支持年轻的研究-临床医生是未来在临床，转化和基础科学研究中取得成功的关键。
A collaborative think tank involving panellists from immuno-oncology networks, clinical/translational investigators and the pharmaceutical industry was held in Siena, Italy, in October 2017 to discuss the evolving immune-oncology landscape, identify selected key challenges, and provide a perspective on the next steps required in the translation of current research and knowledge to clinical reality. While there is a trend of combining new agents (e.g., co-stimulator agonists) with a PD-1/PD-L1 treatment backbone, use of alternative combination therapy approaches should also be considered. While the rapid evolution in systems biology provides a deeper understanding of tumor and tumor microenvironment heterogeneity, there remains the need to identify and define genuinely predictive biomarkers to guide treatment and patient selection. Cross-specialty and cross-sector collaboration, along with a broader collective data-sharing approach are key to optimizing immuno-oncology therapy in clinical practice. Continued support of younger research-clinicians is essential for future success in clinical, translational and basic science investigations.